A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 8,404 shares of BMRN stock, worth $532,981. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,404
Previous 7,237 16.13%
Holding current value
$532,981
Previous $595,000 0.84%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$69.02 - $93.84 $80,546 - $109,511
1,167 Added 16.13%
8,404 $590,000
Q2 2024

Jul 30, 2024

SELL
$74.43 - $92.22 $7.51 Million - $9.3 Million
-100,844 Reduced 93.3%
7,237 $595,000
Q1 2024

May 01, 2024

BUY
$83.81 - $99.0 $4.76 Million - $5.62 Million
56,784 Added 110.7%
108,081 $9.44 Million
Q4 2023

Jan 24, 2024

SELL
$76.22 - $98.51 $3.89 Million - $5.02 Million
-50,979 Reduced 49.84%
51,297 $4.95 Million
Q3 2023

Oct 26, 2023

BUY
$85.07 - $94.48 $115,610 - $128,398
1,359 Added 1.35%
102,276 $9.05 Million
Q2 2023

Aug 10, 2023

SELL
$86.68 - $100.3 $8.74 Million - $10.1 Million
-100,848 Reduced 49.98%
100,917 $8.75 Million
Q1 2023

May 04, 2023

BUY
$87.74 - $117.27 $8.67 Million - $11.6 Million
98,818 Added 95.99%
201,765 $19.6 Million
Q4 2022

Feb 09, 2023

SELL
$80.93 - $108.63 $1.46 Million - $1.95 Million
-17,990 Reduced 14.88%
102,947 $10.7 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $1.02 Million - $1.2 Million
12,409 Added 11.43%
120,937 $10.3 Million
Q2 2022

Jul 26, 2022

SELL
$71.48 - $86.85 $2.18 Million - $2.65 Million
-30,542 Reduced 21.96%
108,528 $8.99 Million
Q1 2022

May 10, 2022

SELL
$74.28 - $92.69 $1.8 Million - $2.24 Million
-24,177 Reduced 14.81%
139,070 $10.7 Million
Q4 2021

Feb 08, 2022

BUY
$71.72 - $91.47 $900,086 - $1.15 Million
12,550 Added 8.33%
163,247 $14.4 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $2.22 Million - $2.53 Million
29,653 Added 24.5%
150,697 $11.6 Million
Q2 2021

Aug 11, 2021

BUY
$75.51 - $84.79 $2.05 Million - $2.3 Million
27,156 Added 28.92%
121,044 $10.1 Million
Q1 2021

May 13, 2021

BUY
$74.73 - $90.69 $2.64 Million - $3.2 Million
35,280 Added 60.2%
93,888 $7.09 Million
Q4 2020

Feb 10, 2021

SELL
$72.61 - $90.2 $1.2 Million - $1.48 Million
-16,459 Reduced 21.93%
58,608 $5.14 Million
Q3 2020

Nov 12, 2020

BUY
$71.87 - $131.03 $1.11 Million - $2.03 Million
15,502 Added 26.03%
75,067 $5.71 Million
Q2 2020

Aug 11, 2020

BUY
$79.55 - $124.22 $873,777 - $1.36 Million
10,984 Added 22.61%
59,565 $7.35 Million
Q1 2020

May 12, 2020

BUY
$71.37 - $96.85 $495,878 - $672,913
6,948 Added 16.69%
48,581 $4.11 Million
Q4 2019

Feb 12, 2020

BUY
$64.27 - $86.37 $508,568 - $683,445
7,913 Added 23.47%
41,633 $3.52 Million
Q3 2019

Nov 12, 2019

BUY
$67.4 - $85.11 $511,026 - $645,304
7,582 Added 29.01%
33,720 $2.27 Million
Q2 2019

Aug 13, 2019

BUY
$80.35 - $93.9 $338,755 - $395,882
4,216 Added 19.23%
26,138 $2.23 Million
Q1 2019

May 13, 2019

BUY
$84.2 - $98.62 $176,651 - $206,904
2,098 Added 10.58%
21,922 $1.94 Million
Q4 2018

Feb 11, 2019

BUY
$80.14 - $106.07 $220,625 - $292,010
2,753 Added 16.13%
19,824 $1.69 Million
Q3 2018

Nov 13, 2018

BUY
$93.92 - $105.72 $322,239 - $362,725
3,431 Added 25.15%
17,071 $1.66 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $145,787 - $189,939
1,918 Added 16.36%
13,640 $1.27 Million
Q1 2018

May 10, 2018

BUY
$77.67 - $92.63 $26,485 - $31,586
341 Added 3.0%
11,722 $951,000
Q4 2017

Feb 12, 2018

BUY
$80.76 - $95.13 $83,182 - $97,983
1,030 Added 9.95%
11,381 $1.02 Million
Q3 2017

Nov 08, 2017

BUY
$80.6 - $94.95 $185,380 - $218,385
2,300 Added 28.57%
10,351 $963,000
Q2 2017

Aug 14, 2017

BUY
N/A
8,051
8,051 $727,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.